Interpretation guidance for MHRA regulatory considerations for phage therapeutic products

References

1. MHRA Regulatory considerations for therapeutic use of bacteriophages in the UK; 2025 https://assets.publishing.service.gov.uk/media/6846c2460392ed9b784c01a5/Regulatory-considerations-therapeutic_by-use-phages.pdf
2. HSE Guidance notes for risk assessment outlined in the Genetically Modified Organisms (Contained Use) Regulations 2014 on the contained use of genetically modified micro-organisms; 2014 https://www.hse.gov.uk/biosafety/gmo/acgm/index.htm
3. HSE The Genetically Modified Organisms (Contained Use) Regulations 2014 L29, 5th. edn HSE Books; 2014
   [Google Scholar]
4. HSESACGM The SACGM Compendium of Guidance HSE Books; 2007
   [Google Scholar]
5. European Medicines AgencyCHMP Guideline on environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs); 2006 https://www.ema.europa.eu/en/environmental-risk-assessments-medicinal-products-containing-or-consisting-genetically-modified-organisms-gmos-scientific-guideline
6. European Medicines Agency EMA’s scientific guidelines on gene therapy help medicine developers prepare marketing authorisation applications for human medicines. n.d https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/multidisciplinary-guidelines/multidisciplinary-gene-therapy
7. European Medicines Agency EMA’S guide on advanced therapy medicinal products; 2021 https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-clinical-development-flowchart_en.pdf
8. ICH Common technical document for the registration of pharmaceuticals for human use M4; 2003 https://www.ich.org/page/ctd
9. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 Suppl 3:3–13 [View Article] [PubMed]
   [Google Scholar]
10. Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J 2009; 11:424–431 [View Article] [PubMed]
    [Google Scholar]
11. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269:20095–20102 [PubMed]
    [Google Scholar]
12. Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 1994; 33:6952–6959 [View Article] [PubMed]
    [Google Scholar]
13. Wei S, Wang A, Cai L, Ma R, Lu L et al. Proteomic analysis of marine bacteriophages: structural conservation, post‐translational modifications, and phage–host interactions. Environ Microbiol 2025; 27:e70099 [View Article]
    [Google Scholar]
14. ICH Quality guidelines. n.d https://www.ich.org/page/quality-guidelines
15. Wakelin-Smith J. Updated data integrity requirements for GLP monitoring programme members; 2021 https://mhrainspectorate.blog.gov.uk/2021/09/27/updated-data-integrity-requirements-for-glp-monitoring-programme-members/
16. European Medicines Agency Guideline on quality aspects of phage therapy medicinal products (Draft); 2025 https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-phage-therapy-medicinal-products_en.pdf
17. Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161:512–526 [View Article] [PubMed]
    [Google Scholar]
18. ICH Specifications: Test procedures and acceptable criteria for biotechnological/biological products Q6B; 1995 https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
19. ICH Pharmaceutical development Q8 (R2); 2009 https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
20. European Medicines AssociationCHMP Guideline on human cell-based medicinal products; 2009 https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-human-cell-based-medicinal-products_en.pdf
21. ICH Quality risk management Q9 (R1); 2023 https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2023_0126_0.pdf
22. MHRA Technical review of MHRA analytical quality by design project; 2019 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/807416/AQbD_Technical_Document_-_Final_04_June_2019.pdf
23. European Commission Enterrpise and Industry Directorate General EudraLex: the rules governing medicinal products in the European Union. Volume 4: EU guidelines to good manufacturing practice medicinal products for human and veterinary use: Annex 19: reference and retention samples 2006
    [Google Scholar]
24. European Directorate for the Quality of Medicines & HealthCare 5.31 Phage therapy medicinal products. European Pharmacopoeia 11.6 2024
    [Google Scholar]
25. European Medicines Agency Quality, safety and efficacy of bacteriophages as veterinary medicines; 2023 https://www.ema.europa.eu/en/quality-safety-and-efficacy-bacteriophages-veterinary-medicines-scientific-guideline
26. ICH The common technical document for the registration of pharmaceuticals for human use: quality Q9 (R1); 2002 https://database.ich.org/sites/default/files/M4Q_R1_Guideline.pdf
27. ICH Good manufacturing practice guide for active pharmaceutical ingredients Q7; 2000 https://database.ich.org/sites/default/files/Q7%20Guideline.pdf
28. ICH Quality of biotechnological products: Analysis of the expression construct in cells used for production of R-DNA derived protein products Q5B; 1995 https://database.ich.org/sites/default/files/Q5B%20Guideline.pdf
29. ICH Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D; 1997 https://database.ich.org/sites/default/files/Q5D%20Guideline.pdf
30. Pirnay JP, Ferry T, Resch G. Recent progress toward the implementation of phage therapy in Western medicine. FEMS Microbiol Rev 2022; 46:fuab040 [View Article] [PubMed]
    [Google Scholar]
31. European Commission EudraLex Guidelines on good manufacturing practice specific to advanced therapy medicinal products. EudraLex the rules governing medicinal products in the European Union. Volume 4. Good Manufacturing Practice 2017
    [Google Scholar]
32. Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (london, england) 2022 pp 629–655 [View Article]
    [Google Scholar]
33. ICH Validation of analytical procedures Q2 (R2); 2023 https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
34. ICH Final IWG concept paper Q2 (R2) and Q14: Q2 (R2): validation of analytical procedures and Q14: analytical procedure development; 2013 https://database.ich.org/sites/default/files/Q2R2-Q14_EWG_Concept_Paper_1.pdf
35. ICH Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances - Scientific guideline Q6A Decision tree #1: establishing acceptance criterion for a specified impurity in a new drug substance; 2000 https://database.ich.org/sites/default/files/Q6A%20Decision%20Tree.pdf
36. ICH Quality of biotechnological products: stability testing of biotechnological/biological products Q5C; 1995 https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf
37. FDA Drugs@FDA glossary of terms; 2017 https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms
38. CPMPEuropean Medicines Agency CPMP position statement on DNA and host cell proteins (HCP) impurities, routine testing versus validation studies; 1997 https://www.ema.europa.eu/en/documents/scientific-guideline/position-statement-dna-and-host-cell-proteins-hcp-impurities-routine-testing-versus-validation-studies-partly-superseded_en.pdf
39. European Medicinces Agency Questions and answers for biological medicinal products; 2025 https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/biological-guidelines/questions-answers-biological-medicinal-products
40. WHO Guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use Annex 4; 2022 https://www.who.int/publications/m/item/guideline-for-the-safe-production-and-quality-control-of-monoclonal-antibodies
41. European Medicines Agency Post-authorisation [guidance]. n.d https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation
42. European Commission EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use EudraLex The Rules Governing Medicinal Products in the European Union, 2010. Volume 4(Annex 13: Investigational Medicinal Products); 2010 https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
43. European Commission Detailed Commission guidelines on good manufacturing practice for investigational medicinal products for human use, pursuant to the second subparagraph of Article 63(1) of Regulation (EU) No 536/2014; 2017 https://health.ec.europa.eu/document/download/a0b206a0-5788-406b-9e20-e0525b16e712_en
44. MHRA Apply for manufacturer or wholesaler of medicines licences; 2024 https://www.gov.uk/guidance/apply-for-manufacturer-or-wholesaler-of-medicines-licences
45. MHRA Rules and Guidance for Pharmaceutical Manufacturers and Distributors (The MHRA Orange Guide) 2022 Pharmaceutical Press; 2022
    [Google Scholar]
46. European Commission EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines. n.d https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
47. ICH Continuous manufacturing of drug substances and drug products Q13; 2022 https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2022_1116.pdf
48. FDA Guidance for industry PAT — a framework for innovative pharmaceutical development, manufacturing, and quality assurance; 2004 https://www.fda.gov/media/71012/download
49. ICH Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E; 2004 https://database.ich.org/sites/default/files/Q5E%20Guideline.pdf
50. European Medicines Agency Committee for advanced therapies, questions and answers: comparability considerations for advanced therapy medicinal products (ATMP); 2019 https://www.ema.europa.eu/en/documents/other/questions-and-answers-comparability-considerations-advanced-therapy-medicinal-products-atmp_en.pdf
51. ICH The common technical document for the registration of pharmaceuticals for human use: safety - M4S (R2) -- nonclinical overview and nonclinical summaries of module 2 -- organisation of module 4; 2002 https://database.ich.org/sites/default/files/M4S_R2_Guideline.pdf
52. ICH Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6 (R1); 1997 https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf
53. ICH Guideline on nonclinical biodistribution considerations for gene therapy products S12; 2023 https://database.ich.org/sites/default/files/ICH_S12_Step4_Guideline_2023_0314_WithCorrection_0.pdf
54. CHMP European Medicines Agency Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products; 2008 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf
55. Fekete EE, Figeys D, Zhang X. Microbiota-directed biotherapeutics: considerations for quality and functional assessment. Gut Microbes 2023; 15:2186671 [View Article] [PubMed]
    [Google Scholar]
56. Pirnay J-P, Djebara S, Steurs G, Griselain J, Cochez C et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol 2024; 9:1434–1453 [View Article] [PubMed]
    [Google Scholar]
57. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol 2020; 11:1951 [View Article] [PubMed]
    [Google Scholar]
58. Sarsarshahi S, Bhattacharya S, Zacharias ZR, Kamel ES, Houtman JCD et al. Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics. J Pharm Sci 2025; 114:103771 [View Article] [PubMed]
    [Google Scholar]
59. ICH Structure and Content of Clinical Study Reports E3; 1995 https://database.ich.org/sites/default/files/E3_Guideline.pdf
60. ICH The common technical document - efficacy guidance for industry M4E (R2); 2017 https://database.ich.org/sites/default/files/M4E_R2__Guideline.pdf
61. MHRA Clinical trials for medicines: apply for authorisation in the UK; 2025 https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk
62. European Medicines AgencyCommittee for Advanced Therapies (CAT) Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products; 2018 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf
63. CHMP European Medicines Agency Guidance on human cell-based medicinal products; 2008 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-human-cell-based-medicinal-products_en.pdf
64. ICH Clinical safety data management E2A - E2F. n.d https://www.ich.org/page/efficacy-guidelines
65. de Bell S, Alejandre JC, Menzel C, Sousa-Silva R, Straka TM et al. Nature-based social prescribing programmes: opportunities, challenges, and facilitators for implementation. Environ Int 2024; 190:108801 [View Article] [PubMed]
    [Google Scholar]
66. NICE NICE health technology evaluations: the manual. 2025 update. NICE process and methods; 2025 https://www.nice.org.uk/process/pmg36/
67. NICE NICE-wide topic prioritisation: the manual. NICE process and methods, 2025 update; 2025 https://www.nice.org.uk/process/pmg46/chapter/update-information
68. NHS England Antimicrobial products subscription model: guidance on commercial arrangements; 2024 https://www.england.nhs.uk/publication/antimicrobial-products-subscription-model-guidance-on-commercial-arrangements/
69. NICE NICE health technology evaluations: the manual, Annex 7: health technology assessment process; 2022 https://www.nice.org.uk/Media/Default/About/what-we-do/Life-sciences/evaluation-framework.pdf